PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents
Status:
Suspended
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase II study is to evaluate the use of labelled RGD ligand in
PET/CT to predict and/or to early assess the efficacy of chemotherapy including an agent with
antiangiogenic effect.
The predictive value of this approach will be determined by independent assessors on basis of
data at the end of the treatment: RECIST 1.1 criteria for CT or MRI, PERCIST criteria for FDG
PET/CT, clinical, endoscopic and histological findings.